Pfizer Inc Q4 2021 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So firstly, just on the oral GLP-1. I wonder if you can confirm the number of pills per day that you'll be using in your Phase 2b study up to that maximum dose of 200 mg per -- twice a day. What's the pill burden for the highest dose? And also on obesity, you've not discussed that today. But do you have the Phase 2a data in-house? I noted that you said you've moved another oral GLP-1 molecule into the clinic. And I'm just interested to know how that asset may differ from the initial danuglipron? And then lastly, just on the guidance. So if I'm thinking about your $4 billion sort of range on your sales guidance, given you've given us the point estimates or thereabouts for the vaccine and the antiviral, should I assume the majority of the flex remaining relates to the base business? And if so, can you help me understand the key moving parts within that element of the business? Which drugs may be a driver of that flex?